A study by Germany-based medical cannabis company Bloomwell found that 94% of respondents who consumed cannabis did so for at least one medical or health reason. The most common reason respondents consumed cannabis was stress relief (approximately 60%), followed by sleep disturbances (50.4%) and pain relief (35%).
However, only 10% of respondents said they had obtained cannabis only from licensed dispensaries in the past year, and the majority (79.6%) said they had a negative experience with the unlicensed market.
Niklas Koupalanis, co-founder and CEO of Bloomwell Group, Bloomwell's holding company, said in a statement that the survey responses indicate that “cannabis has grown rapidly since the enactment of cannabis regulations. “This demonstrates the tremendous potential and room for growth for the country's medical cannabis industry.” On April 1, 2024, the Cannabis Act was enacted, rescheduling cannabis as a non-narcotic drug. He added that according to data, “more than 20 million people in Germany could benefit from medical cannabis therapy.”
According to the survey, 30.9% reported purchasing low-quality cannabis, 29% feared that illegally obtained cannabis would negatively impact their health, and 39.7% reported purchasing low-quality cannabis. 14.8% had problems with proper dosing, and 26.3% had purchased contaminated cannabis.
The survey also found that 91.7% of respondents said they would prefer cannabis treatment via an app that delivers medical cannabis from pharmacies in Germany at low prices. “Patients no longer need to rely on the illicit market nor should they be pushed in that direction,” Koupalanis said.
Additionally, one-third of consumers surveyed had already been diagnosed with a qualifying medical condition by a doctor, and 21.2% had already consulted a doctor about medical cannabis, but their doctor did not recommend medical cannabis as a treatment. It turned out that it was not prescribed. . More than a quarter (25.2%) said their doctor was unable to resolve their health problems, but only a minority of respondents said they had “no problems” finding a doctor who could adequately support their medical cannabis treatment. Only 9.2% of those surveyed did so.
Dr. Julian Wichman, co-founder of Bloomwell Group and CEO of Bloomwell, said: “These findings place medical cannabis on an equal footing with other modern medical therapies. It emphasizes the need.”
“However, for too many doctors in Germany, medical cannabis remains a taboo subject,” Wichmann added. “To normalize cannabis use and remove outdated stigma, medical cannabis education is needed for patients as well as medical professionals.”
Get the latest cannabis business news every day. Subscribe
Have an additional perspective to share? Send us a message and let us know. If your comment is selected by an editor, it may be featured here.
Perspectives to add? Please use the form below to suggest revisions or submit comments for review.
TG Branfalt
TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York and also teaches media studies at a local university.
Ganjapreneur is made possible by the following partners:
Source link
